AnGes Takes DNA Vaccine Tack As It Enters Virus R&D Fray

Japan Venture Joins Others In Same Approach

Japanese bioventure goes down the DNA vaccine route, along with several others worldwide, pointing to potential development speed and safety advantages.

Scientists
Japanese, Other Firms Join Coronavirus Fight • Source: Shutterstock

In another potential arrow in the growing pharma R&D quiver against the spreading coronavirus, AnGes Inc. is working with Osaka University on a potential prophylactic DNA vaccine against the new coronavirus, in an effort making use of the Japanese bioventure's plasmid DNA experience.

Such vaccines have the advantage of usually shorter production lead times versus standard attenuated vaccines and those using recombinant virus...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Japan

More from Focus On Asia